Cancers, Free Full-Text
Por um escritor misterioso
Descrição
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.
Destination Healthy Skin Toolkit - The Skin Cancer Foundation
What is secondary lung cancer?
Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
8 Ways to prevent cancer & be healthy -Siteman Cancer Center
Time trial: A prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers – topic of research paper in Clinical medicine. Download scholarly
Hallmarks of Cancer: The Next Generation: Cell
Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
An Introduction to Human Cancers
Join a FREE Breast Cancer Survivorship Program
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes, Breast Cancer Research
:max_bytes(150000):strip_icc()/illo_normal-cells-cancer-cells-596cdd256f53ba00111a65bb.png)
Cancer Cells vs. Normal Cells: How Are They Different?
